Assignee
NURIX THERAPEUTICS INC
US·21 granted patents·19 pending applications·68 citations·filing 2019–2025
Top patents by PatentIndex Score
40 records- 0197US11530229B2Cyano cyclobutyl compounds for CBL-B inhibition and uses thereofNURIX THERAPEUTICS INC·Filed 2020·Granted Dec 20, 2022·12 cites·71 claims
- 0297US11464802B23-substituted piperidine compounds for Cbl-b inhibition, and use thereofNURIX THERAPEUTICS INC·Filed 2020·Granted Oct 11, 2022·14 cites·53 claims
- 0397US11401267B2Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereofNURIX THERAPEUTICS INC·Filed 2020·Granted Aug 2, 2022·11 cites·32 claims
- 0494US11951133B23-substituted piperidine compounds for Cbl-b inhibition, and use thereofNURIX THERAPEUTICS INC·Filed 2022·Granted Apr 9, 2024·2 cites·36 claims
- 0594US11866442B2Bifunctional compounds for degrading BTK via ubiquitin proteosome pathwayNURIX THERAPEUTICS INC·Filed 2022·Granted Jan 9, 2024·5 cites·37 claims
- 0693US11479556B1Bifunctional compounds for degrading BTK via ubiquitin proteosome pathwayNURIX THERAPEUTICS INC·Filed 2019·Granted Oct 25, 2022·9 cites·106 claims
- 0792US12485144B23-substituted piperidine compounds for Cbl-b inhibition, and use thereofNURIX THERAPEUTICS INC·Filed 2024·Granted Dec 2, 2025·1 cites·40 claims
- 0892US12049471B2Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereofNURIX THERAPEUTICS INC·Filed 2022·Granted Jul 30, 2024·1 cites·16 claims
- 0991US11739101B2Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereofNURIX THERAPEUTICS INC·Filed 2021·Granted Aug 29, 2023·3 cites·40 claims
- 1090US12234230B2Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereofNURIX THERAPEUTICS INC·Filed 2022·Granted Feb 25, 2025·1 cites·5 claims
- 1188US11976071B2Substituted pyrrolo[1,2-b]pyridazines as bifunctional degraders of interleukin-1 receptor-associated kinasesNURIX THERAPEUTICS INC·Filed 2022·Granted May 7, 2024·2 cites·14 claims
- 1288US11820781B2Bifunctional compounds for degrading BTK via ubiquitin proteosome pathwayNURIX THERAPEUTICS INC·Filed 2020·Granted Nov 21, 2023·5 cites·34 claims
- 1388US2026035378A1Bifunctional compounds for degrading btk via ubiquitin proteosome pathwayNURIX THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 1483US12121540B2CBL inhibitors and compositions for use in adoptive cell therapyNURIX THERAPEUTICS INC·Filed 2020·Granted Oct 22, 2024·1 cites·48 claims
- 1583US12016860B2Combination therapies with Cbl-b inhibitor compoundsNURIX THERAPEUTICS INC·Filed 2022·Granted Jun 25, 2024·1 cites·4 claims
- 1681US12583862B2Bifunctional compounds for degrading BTK via ubiquitin proteosome pathwayNURIX THERAPEUTICS INC·Filed 2023·Granted Mar 24, 2026·0 cites·19 claims
- 1781US2025136590A1Substituted benzyl-triazole compounds for cbl-b inhibition, and further uses thereofNURIX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1880US2024409555A1Cyano cyclobutyl compounds for cbl-b inhibition and uses thereofNURIX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1976US12570662B2Substituted pyrrolo[1,2-b]pyridazines as bifunctional degraders of interleukin-1 receptor-associated kinasesNURIX THERAPEUTICS INC·Filed 2024·Granted Mar 10, 2026·0 cites·20 claims
- 2073US2024400587A1Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereofNURIX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2171US12377106B2Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading BTKNURIX THERAPEUTICS INC·Filed 2022·Granted Aug 5, 2025·0 cites·34 claims
- 2269US2025161303A1Combination therapies with cbl-b inhibitor compoundsNURIX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2368US12091426B2Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereofNURIX THERAPEUTICS INC·Filed 2022·Granted Sep 17, 2024·0 cites·29 claims
- 2467US2024025923A1Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereofNURIX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2565US2023414598A1Combination therapies with cbl-b inhibitor compounds and antiemetic agentsNURIX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2663US2025136579A1Salts and free bases of bifunctional compound and polymorph forms thereofNURIX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2760US2025017922A1Bifunctional compounds for degrading btk with enhanced imid activityNURIX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2858US2023158151A1Compounds for inhibiting or degrading target proteins, compositions, comprising the same, methods of their making, and methods of their useNURIX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2958US2024336595A1Bifunctional compounds for degrading btk with diminished imid activityNURIX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3057US2024279202A1Compounds for inhibiting or degrading itk, compositions, comprising the same methods of their making and methods of their useNURIX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3156US2023355599A1Biomarkers for cbl, and compositions and methods for their useNURIX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3256US2025002489A1Bifunctional compounds for degrading itk via ubiquitin proteosome pathwayNURIX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3355US12594263B2CBL inhibitors and compositions for expansion of immune cellsNURIX THERAPEUTICS INC·Filed 2020·Granted Apr 7, 2026·0 cites·31 claims
- 3454US12528814B2Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereofNURIX THERAPEUTICS INC·Filed 2021·Granted Jan 20, 2026·0 cites·57 claims
- 3553US2025009731A1Toll-like receptor therapy combinations with cbl-b inhibitor compoundsNURIX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3651US2022387395A1Urea, amide, and substituted heteroaryl compounds for cbl-b inhibitionNURIX THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3750US2022324835A1Inhibitors of cbl-b and methods of use thereofNURIX THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3850US2025051344A1Bifunctional selective degraders of smarca2 and therapeutic uses thereofNURIX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3944US2023024442A1Bifunctional compounds for grading btk via ubiquitin proteosome pathwayNURIX THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4043US12582722B2Bifunctional compounds for degrading BTK via ubiquitin proteosome pathwayNURIX THERAPEUTICS INC·Filed 2020·Granted Mar 24, 2026·0 cites·21 claims
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →